- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05443646
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
A Phase II Study of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy With Concurrent Chemotherapy for Patients With Limited Stage Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All eligible patients after screening will receive up to four cycles chemotherapy. Recommended regimens are etoposide 100 mg/m2 intravenously on day 1-3 in combination with cisplatin 75 mg/m2 intravenously on day 1 or carboplatin AUC=5 every 3 weeks.
A total of 45Gy in 15 fractions over 3 weeks will be delivered. PCI is routinely scheduled for patients without progression after chemoradiotherapy, and hippocampal avoidance is highly recommended. 25Gy in 10 fractions over 2 weeks to the brain will be prescribed. Intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) technique are required. Patients without disease progression will receive an intravenous infusion of serplulimab 300mg every 3 weeks. Treatment of serplulimab should be continued until disease progression, intolerable toxicity, withdrawal of consent, or to a maximum of 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Nan Bi, Doctor
- Phone Number: 86010-87788799
- Email: binan_email@163.com
Study Locations
-
-
Heilongjiang
-
Jiamusi, Heilongjiang, China, 154007
- Recruiting
- Jiamusi Cancer Hospital
-
Contact:
- Xiaohong Zhou
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030013
- Recruiting
- Shanxi Province Cancer Hospital
-
Contact:
- Jianzhong Cao
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-75 years; ECOG score 0-1.
- Histologically or cytologically confirmed small cell lung cancer.
- Limited stage, defined as the tumor confined to one side of the thoracic cavity including ipsilateral hilar, bilateral mediastinal, and bilateral supraclavicular lymph nodes, (metastatic lymph nodes are defined as short diameter ≥ 1 cm or increased metabolism on PET-CT considering metastatic lymph nodes); unless cytologically confirmed malignant pleural effusion, the thickness of pleural effusion on chest CT is less than 1 cm; (stage I-IIIB without intrapulmonary metastasis in the 7th edition of AJCC staging in 2009) .
- No other previous anti-tumor history, at least 3 months of expected survival.
- No serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function.
Exclusion Criteria:
- Histologically or cytologically confirmed mixed SCLC.
- Subjects suitable for surgery. Subjects who are suitable for surgery but refuse surgical treatment can be included.
- Patients who have previously received systematic anti-tumor treatments for small cell lung cancer, including but not limited to radiotherapy, chemotherapy, and immunotherapy.
- Patients with other active malignancies within 5 years or at the same time.
- Subjects with known history of severe allergy to any monoclonal antibody.
- Subjects with known anaphylaxis to carboplatin/cisplatin or etoposide.
- In the judgment of the investigator, subjects who have any other factors that may lead to a premature discontinuation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLX10 (Serplulimab) Consolidation After Chemotherapy Concurrent Hypofractionated Radiotherapy
Participants will receive at least 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) concurrently with Hypofractionated Radiotherapy, followed by HLX10 300 mg every 3 weeks (Q3W) with maximum 1 years or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
|
HLX10 is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. 300mg Q3W
Other Names:
25Gy/2.5Gy/2week
45Gy/3Gy/3week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: up to 12 months
|
To evaluate the progression-free survival (PFS) of HLX10 (Serplulimab) consolidation therapy after concurrent hypofractionated radiotherapy with chemotherapy in limited-stage small cell lung cancer according to RECIST 1.1 criteria
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival(OS)
Time Frame: up to 24 months
|
Overall survival time is defined as the time from the date of the patient's first dose of HLX10 to the date of any documented death due to any cause.
|
up to 24 months
|
Objective response rate (ORR)
Time Frame: up to 24 months
|
Proportion of subjects achieving a best response of complete response (CR) and partial response (PR) as assessed by RECIST 1.1.
|
up to 24 months
|
Time to treatment failure (TTF)
Time Frame: up to 12 months
|
Time to disease progression, death, withdrawal due to adverse events, patient refusal to continue the study, or use of a new treatment from the first HLX10 administration.
|
up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nan Bi, Doctor, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASTRUM-LC01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limited Stage Small Cell Lung Cancer
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
European Organisation for Research and Treatment...UNICANCERRecruitingExtensive-stage Small-cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited Kingdom, Belgium, Switzerland, Italy, France, Germany, Poland, Spain, Austria
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedSmall Cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive StageFrance
-
Vanderbilt-Ingram Cancer CenterMerck Sharp & Dohme LLCRecruitingLimited Stage Lung Small Cell Carcinoma | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung CancerUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Limited Stage Lung Small Cell Carcinoma | Stage I Lung Cancer AJCC v8United States, Japan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSCLC | Small-cell Lung Cancer | Small Cell Lung Cancer Limited StageUnited States
-
National Cancer Institute (NCI)CompletedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited States
Clinical Trials on HLX10
-
Shanghai Henlius BiotechRecruitingSquamous Non-small-cell Lung CancerChina
-
Shandong UniversityRecruiting
-
Zhejiang Cancer HospitalRecruitingExtensive Stage Lung Small Cell CancerChina
-
Shanghai Henlius BiotechRecruitingNon Small Cell Lung CancerChina
-
Shanghai Henlius BiotechUnknown
-
RenJi HospitalShanghai Zhongshan HospitalNot yet recruitingFirst-line Treatment of Non-clear Renal Cell Carcinoma
-
Shanghai Henlius BiotechNot yet recruiting
-
Shanghai Henlius BiotechActive, not recruitingAdvanced or Metastatic Solid TumorsAustralia
-
Henlix, IncUnknown
-
Shanghai Henlius BiotechRecruiting